Foundation-funded Study Supports Hypothesis That Davunetide Prevents Cortical Thinning in Brains of Schizophrenia Patients

Printer-friendly versionPrinter-friendly version
Jeffrey Lieberman, M.D.
Jeffrey Lieberman, MD

Foundation Scientific Council Member Jeffrey Lieberman, M.D. leads team in recent study using magnetic resonance imaging (MRI) data to measure the thickness of the cortex in specific regions of the brain in schizophrenia patients.

Dr. Lieberman explained that schizophrenia is a progressive neurodegenerative disease in which cortical thinning is believed to be responsible for some of the clinical symptoms and that this new finding supports the hypothesis that davunetide can prevent brain atrophy. 

Read more

Add new comment

comments

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Please note that researchers cannot give specific recommendations or advice about treatment; diagnosis and treatment are complex and highly individualized processes that require comprehensive face-to- face assessment. Please visit our "Ask an Expert" section to see a list of Q & A with NARSAD Grantees.
By submitting this form, you accept the Mollom privacy policy.